Phase 2 Cardiomyopathy Trial, Recruiting NCT03593317 Sponsor: Hospices Civils de Lyon Condition: Cardiomyopathy
Back to Cardiomyopathy

Phase 2 Cardiomyopathy Trial, Recruiting

NCT03593317
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who are older than 18 years of age
  • People who have been diagnosed with a heart condition called ARVD (a disease affecting the right side of the heart), confirmed using specific international diagnostic guidelines that require a combination of major and minor diagnostic findings
  • People whose heart is pumping at least 40% of its normal capacity (confirmed by heart scan)
  • People who are willing and able to give written consent to participate

Who may not be able to join:

  • People who are under legal/judicial protection
  • Women who are pregnant, breastfeeding, or capable of becoming pregnant and who have not agreed to use highly effective contraception throughout the study (women are considered post-menopausal after at least 24 consecutive months without a period if aged 55 or under, or 12 months if older than 55, or if surgically sterilised)
  • People who do not have health insurance
  • People with severe right-sided heart failure where the right heart chamber is enlarged beyond a certain size
  • People who cannot safely take a medication called spironolactone due to conditions such as kidney problems, high potassium levels in the blood, no urine output, advanced liver disease, a condition called Addison's Disease, a known allergy or sensitivity to spironolactone or its ingredients, certain sugar absorption problems, or those already taking certain other medications that interact with it (confirm with trial site)
  • People who must take a specific combination of certain blood pressure medications together (confirm with trial site)
  • People currently experiencing an active phase of a serious body-wide illness
  • People with an underactive thyroid that is not yet treated or controlled
  • People with an acute (sudden/active) overactive thyroid
  • People whose right heart chamber volume is measured as normal (confirm with trial site)
  • People who have had a heart transplant
  • People who have difficulty swallowing
  • People already participating in another clinical trial that could affect this study's results

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 21 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Philippe Chevalier, MD, PhD, Hospices Civils de Lyon

Phone: 426739447

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Registry
ClinicalTrials.gov
Start date
20 December 2024
Est. completion
1 December 2027

Where this trial is recruiting

🇫🇷 France

Primary endpoints

Right ventricle longitudinal strain measured by echocardiography; Right ventricle infundibulum diameter measured by echocardiography; number of ventricular extrasystoles > 500 on 24h-Holter ECG

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 21 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov